IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2025 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 12.810-13.010 for the period, compared to the consensus estimate of 12.620. The company issued revenue guidance of $4.3 billion-$4.3 billion, compared to the consensus revenue estimate of $4.2 billion.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $629.51 on Monday. The firm has a market cap of $50.36 billion, a price-to-earnings ratio of 52.42, a P/E/G ratio of 4.06 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $688.12. The firm’s 50-day simple moving average is $637.89 and its two-hundred day simple moving average is $569.77.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.26. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts forecast that IDEXX Laboratories will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. UBS Group assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, October 1st. They set a “neutral” rating and a $720.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Finally, Stifel Nicolaus upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and lifted their target price for the company from $640.00 to $700.00 in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $662.50.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,200 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the sale, the executive vice president directly owned 16,807 shares in the company, valued at $11,034,299.71. This represents a 6.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director owned 262 shares of the company’s stock, valued at $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 over the last ninety days. Insiders own 0.98% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. Empowered Funds LLC raised its holdings in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at $265,000. Jump Financial LLC raised its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after buying an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at $164,000. Finally, Sei Investments Co. increased its position in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.